Feed Articles

Pfizer in the spotlight: How does the pharmaceutical leader face market challenges and what to expect?

In recent trading sessions, we've seen interesting developments in shares of pharmaceutical company Pfizer$PFE ).

Pfizer's stock losses over the past month amount to 4.31%, which is in contrast to the 4.24% growth of the medical sector and the S&P 500 index, which gained 4.89%, indicating some challenges Pfizer faces in the market.

However, this leads to the question of whether to buy PFE stock later this year.

Investors are now turning their attention to the company's upcoming earnings, which will be released on January 30, 2024. The company's earnings per share (EPS) is expected to be -0.18 dollars, down 115.7% from the same quarter last year. Revenue is estimated to be $14.3 billion, indicating a decrease of 41.1% compared to the same period last year.

For 2024, Zacks Consensus Estimates expect earnings of $1.53 per share and revenue of $58.67 billion, a shift of -76.75% and -41.53% from a year ago period.

Despite the challenges in the pharmaceutical and medical sectors, Pfizer maintains a solid position. Pfizer ranks in the top 22% of industries with over 250 industries.

Conclusion:

Pfizer stock is currently going through a period of challenges, as indicated by recent losses in value. Although the pharmaceutical giant is facing market pressures, many investors are still keeping a close eye on the company's upcoming results, which will be a key moment for its future direction.

The company's earnings per share and revenue for the final quarter of 2023 are expected to show a significant decline. This data will be important for investors trying to understand how Pfizer is responding to current market challenges and what its potential is going forward.

▪️◾◼️◾▪️

You will find a lot of inspiration on Bulios, but the final stock selection and portfolio construction is of course up to you, so always do a thorough analysis of your own. Thepractical tools within the Bulios Blackmembership are always at your disposal.

Source.

Stocks mentioned

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

These 3 Stocks Raised Their Dividends During the 2008 Crisis and COVID. One Pays Every Month

When companies were canceling shareholder payouts in 2009 and again during the pandemic, these three railway companies were raising them instead. Today they offer yields of 2.1% to 5.7% a year.

MC
Milan Charvat
· 6h
Read more
BLACK

She designs drugs with AI, and Cathie Wood wanted her at $16. Today it's $14

An AI-designed cancer drug reached patients in two years. Its maker raised $172 million on the stock market, and funds linked to Cathie Wood and Druckenmiller wanted shares. Then the price fell 62% in three weeks.

KJ
Kryštof Jáně
· 10h
Read more
BLACK

Americans Have Stopped Buying on Credit. Which Stocks Will Take the Hit?

The monthly payment on a new car in the US has climbed to $823, and auto dealers' sales fell 1.6% in October. In the same week, Target reported its fastest sales growth in five years. Meanwhile, the market expects the Fed to make credit even more expensive in three weeks.

MC
Milan Charvat
· 11h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy